VK2735: Trials and FDA Status
VK2735 is a glp-1/gip dual agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational
- Phase
- Phase 3
- Sponsor
- Viking Therapeutics
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT06068946, NCT06828055, NCT07104500, NCT07104383
Reported results
- 2026VENTURE phase 2 (Obesity 2026): weight change at 13 weeks“Mean weight reduction with active treatment ranged from 9.2 kg (2.5 mg dose) to 14.6 kg (15 mg dose), corresponding to 9.1% and 14.7% weight reductions, respectively; the placebo group had a 1.8 kg (1.7%) reduction”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- NCT07104500 (VANQUISH 1; Phase 3): primary completion (estimated)
- NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2); Phase 3): primary completion (estimated)
- Viking reports VANQUISH-1 and VANQUISH-2 phase 3 trials fully enrolled
- Published in Obesity (Silver Spring, Md.) (2026): Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
- NCT07104500 (VANQUISH 1; Phase 3): first posted on ClinicalTrials.gov
- NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2); Phase 3): first posted on ClinicalTrials.gov
- NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing); Phase 2): primary completion
- NCT07104500 (VANQUISH 1; Phase 3): study start
- NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2); Phase 3): study start
- NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing); Phase 2): first posted on ClinicalTrials.gov
- NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing); Phase 2): study start
- NCT06068946 (VENTURE; Phase 2): primary completion
- NCT06068946 (VENTURE; Phase 2): first posted on ClinicalTrials.gov
- NCT06068946 (VENTURE; Phase 2): study start
What the VK2735 registry entries specify
VANQUISH-1 (NCT07104500) is titled as a phase 3, randomised, double-blind, placebo-controlled 78-week study of subcutaneous VK2735 in people without type 2 diabetes who are obese, or overweight with a weight-related condition.[3]
VANQUISH-1 plans 4500 participants.[3]
VANQUISH-1 is active, not recruiting: it started 2025-06-23 and primary completion is estimated for 2027-07-01.[3]
Viking says VANQUISH participants are randomised to weekly VK2735 arms of 7.5 mg, 12.5 mg and 17.5 mg, or placebo.[6]
VANQUISH-2, in type 2 diabetes, plans 1100 participants.[4]
Viking reports that VANQUISH-1 enrolled more than 4,500 patients, exceeding the original target.[6]
Primary endpoint and trial length
VANQUISH-1's primary outcome is percentage change in body weight from baseline after 78 weeks of treatment.[3]
VANQUISH-1 spans an estimated 105 weeks from start to primary completion.
Calculated from NCT07104500 start 2025-06-23, primary completion 2027-07-01, type ESTIMATED. Formula: weeks = round((primary completion date - start date) / 7 days)
Results and sponsor statements
In the phase 2 VENTURE trial, mean weight reduction ranged from 9.2 kg on 2.5 mg to 14.6 kg on 15 mg (9.1% to 14.7%), against 1.8 kg (1.7%) on placebo.[5]
Viking describes VK2735 as a dual agonist of the GLP-1 and GIP receptors.[6]
Common questions
Is VK2735 in phase 3?
Yes. Viking reports that VANQUISH-1 and VANQUISH-2 are both fully enrolled.[6]
Sources
- 1VENTURE: VK2735 for Weight Management Phase 2 (NCT06068946)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 2VK2735 for Weight Management Phase 2 (Venture Oral Dosing) (NCT06828055)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
- 3VANQUISH 1: VK2735 for Weight Management Phase 3 (NCT07104500)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
- 4VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (NCT07104383)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
- 5Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring, Md.) · 2026PMID 41508550Accessed 2 Oct 2026
- 6Viking reports VANQUISH-1 and VANQUISH-2 phase 3 trials fully enrolledViking Therapeutics (press release) · 2026ir.vikingtherapeutics.comAccessed 2 Oct 2026
Found an error? Report a correction.